Welcome to our dedicated page for ARCELLX SEC filings (Ticker: ACLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcellx, Inc. filings document the company's completed acquisition by Gilead Sciences and the related changes to its public-company status. The Form 8-K record covers completion of the transaction, material-event disclosure, capital-structure matters, and prior operating and financial results.
Arcellx's later regulatory record includes a Form 25 for removal of its common stock from Nasdaq listing and registration, followed by a Form 15 terminating or suspending Exchange Act reporting obligations for the class of securities. These filings establish the company's transition from a Nasdaq-listed biotechnology issuer to a wholly owned subsidiary with one holder of record.
A shareholder of ACLX has filed a notice to sell 7,437 shares of common stock through E-TRADE Financial Corporation on or around 01/13/2026 on NASDAQ. The filing shows these shares are part of 57,917,336 common shares outstanding. The seller, Christopher Heery, acquired 16,520 shares as restricted stock units from the issuer on 01/03/2026, with payment noted as N/A. Over the prior three months, he sold 340 shares of common stock on 11/17/2025 for gross proceeds of 30,600.00 and 6,131 shares on 01/12/2026 for gross proceeds of 393,286.14. By signing, the seller represents that he is not aware of any undisclosed material adverse information about ACLX.
Arcellx, Inc.’s Chief Medical Officer Christopher Heery reported RSU vesting and a related share sale. On 01/03/2026 he acquired 16,520 shares of Common Stock at an exercise price of $0, reflecting settlement of previously granted restricted stock units, each representing one share.
On 01/13/2026 he sold 7,437 shares of Common Stock at a weighted average price of $65.512 per share in a broker-assisted transaction to satisfy tax withholding obligations tied to the RSU vesting. After these transactions, he directly beneficially owns 29,631 shares of Arcellx Common Stock.
Arcellx, Inc. chief medical officer Christopher Heery reported two equity transactions in company stock. On 01/02/2026, he exercised options coded "M" for 13,021 shares of common stock at a price of $0 per share, increasing his directly held position to 13,615 shares.
On 01/12/2026, he executed a broker-assisted sale coded "S" of 6,131 common shares at a weighted average price of $64.1471 per share to cover tax withholding obligations tied to restricted stock unit vesting. Following these transactions, he directly owned 37,068 shares of Arcellx common stock.
ACLX filed a notice under Rule 144 indicating that an insider plans to sell 6,131 shares of common stock through E-TRADE on or about 01/12/2026 on NASDAQ, with an aggregate market value of $393,286.14 and 57,917,336 shares outstanding. These shares relate to 13,021 common shares acquired on 01/02/2026 via restricted stock units from the issuer. Over the prior three months, Christopher Heery sold 340 common shares on 11/17/2025 for gross proceeds of $30,600. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about the issuer.
Arcellx, Inc. reported insider equity activity by its chief medical officer, Christopher Heery. On January 2, 2026, he received an award of 67,708 restricted stock units (RSUs), each representing a contingent right to one share of common stock, vesting in equal annual installments over four years if he remains a service provider.
On January 2, 3 and 6, 2026, previously granted RSUs were converted to common stock in transactions coded "M," resulting in acquisitions of 13,021, 16,520 and 13,064 common shares, respectively, all at a stated price of $0 per share. Following these transactions, Heery held 43,199 shares of common stock directly, along with RSU holdings shown in the derivative table.
Arcellx, Inc. reported an insider stock transaction by its chief medical officer on a Form 4. On November 17, 2025, the officer sold 340 shares of common stock at $90 per share, leaving 284 shares beneficially owned directly after the sale. The filing notes that this sale was carried out under a pre-arranged Rule 10b5-1 trading plan that the reporting person entered into on March 23, 2025, which is designed to allow insiders to sell stock according to a preset schedule.
Arcellx, Inc. reported Q3 2025 results. Collaboration revenue was $4.9 million, down from $26.0 million a year ago as iMMagine-1 dosing and manufacturing wound down. The company posted a net loss of $55.8 million (basic and diluted $(0.99) per share) versus a $25.9 million loss last year.
Operating expenses rose to $66.7 million, with R&D $35.1 million (lower on reduced anito-cel trial activity) and G&A $31.6 million (higher commercial readiness and personnel costs). Other income was $6.0 million on interest.
Liquidity remained solid with $576.0 million in cash, cash equivalents and marketable securities at quarter-end, and management believes this funds operations into 2028. Contract liabilities to the Kite collaboration totaled $112.2 million. Year-to-date, Arcellx raised $131.6 million via its at-the-market program (1,905,715 shares). As of October 31, 2025, shares outstanding were 57,822,871. The company continues co-development of anito-cel with Kite, including the global Phase 3 iMMagine-3 in multiple myeloma.
Arcellx, Inc. furnished a current report on Form 8-K to announce that it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information under Item 2.02, including Exhibit 99.1, is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference unless specifically stated. The report lists ACLX as the trading symbol on The Nasdaq Stock Market LLC and is signed by Chief Executive Officer Rami Elghandour on November 5, 2025.
Arcellx (ACLX) reported an insider transaction by its Chief Financial Officer. On 10/15/2025, the CFO sold 5,364 shares of common stock at a weighted average price of $91.0357, with trades ranging from $90.99 to $91.19, under a Rule 10b5-1 trading plan entered on March 21, 2025.
Following the sale, the officer beneficially owns 8,466 shares, held directly.
Arcellx (ACLX) reported insider activity by its Chief Financial Officer. On 10/03/2025, the CFO sold 4,882 shares of common stock at a weighted average price of $86.0036. On 10/06/2025, the CFO sold an additional 1,064 shares at a weighted average price of $86.2155. These sales were made under a Rule 10b5-1 trading plan entered on March 21, 2025. Following the transactions, the officer directly beneficially owned 13,830 shares.